Logo image of MYOV

Myovant Sciences Ltd (MYOV) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:MYOV - BMG637AM1024 - Common Stock

26.98 USD
-0.01 (-0.04%)
Last: 3/9/2023, 8:04:00 PM
26.98 USD
0 (0%)
After Hours: 3/9/2023, 8:04:00 PM
Fundamental Rating

2

MYOV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of MYOV have multiple concerns. MYOV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MYOV had negative earnings in the past year.
MYOV had a negative operating cash flow in the past year.
In the past 5 years MYOV always reported negative net income.
In the past 5 years MYOV reported 4 times negative operating cash flow.
MYOV Yearly Net Income VS EBIT VS OCF VS FCFMYOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M

1.2 Ratios

The profitability ratios for MYOV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYOV Yearly ROA, ROE, ROICMYOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

With an excellent Gross Margin value of 73.03%, MYOV belongs to the best of the industry, outperforming 84.43% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MYOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYOV Yearly Profit, Operating, Gross MarginsMYOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

1

2. Health

2.1 Basic Checks

MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYOV has been increased compared to 1 year ago.
Compared to 1 year ago, MYOV has a worse debt to assets ratio.
MYOV Yearly Shares OutstandingMYOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
MYOV Yearly Total Debt VS Total AssetsMYOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.98, we must say that MYOV is in the distress zone and has some risk of bankruptcy.
MYOV's Altman-Z score of -2.98 is on the low side compared to the rest of the industry. MYOV is outperformed by 60.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.98
ROIC/WACCN/A
WACC7.64%
MYOV Yearly LT Debt VS Equity VS FCFMYOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

2.3 Liquidity

A Current Ratio of 1.57 indicates that MYOV should not have too much problems paying its short term obligations.
MYOV has a Current ratio of 1.57. This is amonst the worse of the industry: MYOV underperforms 84.43% of its industry peers.
MYOV has a Quick Ratio of 1.45. This is a normal value and indicates that MYOV is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MYOV (1.45) is worse than 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.45
MYOV Yearly Current Assets VS Current LiabilitesMYOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.67% over the past year.
MYOV shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.46%.
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%

3.2 Future

Based on estimates for the next years, MYOV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.08% on average per year.
The Revenue is expected to grow by 45.18% on average over the next years. This is a very strong growth
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%

3.3 Evolution

MYOV Yearly Revenue VS EstimatesMYOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B
MYOV Yearly EPS VS EstimatesMYOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYOV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYOV Price Earnings VS Forward Price EarningsMYOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYOV Per share dataMYOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as MYOV's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.59%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Myovant Sciences Ltd

NYSE:MYOV (3/9/2023, 8:04:00 PM)

After market: 26.98 0 (0%)

26.98

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-26 2023-01-26/amc
Earnings (Next)05-08 2023-05-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners55.37%
Ins Owner Change0%
Market Cap2.62B
Revenue(TTM)379.11M
Net Income(TTM)-183.77M
Analysts76
Price Target27.54 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.15%
Min EPS beat(2)-21.77%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)1.97%
Min EPS beat(4)-21.77%
Max EPS beat(4)32.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-4%
Max Revenue beat(2)9.95%
Revenue beat(4)2
Avg Revenue beat(4)4.58%
Min Revenue beat(4)-12.72%
Max Revenue beat(4)25.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.22%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS3.9
BVpS-5.74
TBVpS-5.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.45
Altman-Z -2.98
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)67.93%
Cap/Depr(5y)160.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%
EBIT growth 1Y30.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.53%
EBIT Next 3Y15.08%
EBIT Next 5Y36.76%
FCF growth 1Y-161.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.74%
OCF growth 3YN/A
OCF growth 5YN/A

Myovant Sciences Ltd / MYOV FAQ

What is the fundamental rating for MYOV stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYOV.


Can you provide the valuation status for Myovant Sciences Ltd?

ChartMill assigns a valuation rating of 0 / 10 to Myovant Sciences Ltd (MYOV). This can be considered as Overvalued.


What is the profitability of MYOV stock?

Myovant Sciences Ltd (MYOV) has a profitability rating of 0 / 10.


What is the expected EPS growth for Myovant Sciences Ltd (MYOV) stock?

The Earnings per Share (EPS) of Myovant Sciences Ltd (MYOV) is expected to grow by 19.42% in the next year.